SAFE in Recovery Act

Advocated for increased FY24 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY24 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M) Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Worked on draft legislation that would provide Medicare coverage for evidence-based residential SUD services Supported H.R.1502 - Comprehensive Opioid Recovery Centers Reauthorization Act of 2023, in its entirety Advocated for removal of in-person evaluation requirement in proposed telemedicine rules by the DEA and worked on related draft legislation Opposed proposed changes to the STAR-LRP program in S.462 - the Mental Health Professionals Workforce Shortage Loan Repayment Act of 2023 Advocated for removal of a lifetime ban that prevents individuals convicted of a drug felony from receiving Supplemental Nutritional Assistance Program (SNAP) or Temporary Assistance for Needy Families TANF) as part of the next Farm Bill. Advocated for various substance use disorder workforce and coverage policy changes, including some of which appear in H.R. 4531, the Support for Patients and Communities Reauthorization Act. Advocated for certain annual increases for Medicare office based SUD bundled codes. ASAM signed a letter in support of S. 1378, Connecting Our Medical Providers with Links to Expand Tailored and Effective Act (the "COMPLETE Act"), which would advance collaborative care models. ASAM signed a letter sent by a broad coalition of health care clinicians, patient advocates, and other stakeholders, urging Congressional leaders to support the Centers for Medicare and Medicaid Services' (CMS) proposal to implement a Medicare billing code, known as G2211, in 2024. ASAM submitted comments to the Centers for Medicare and Medicaid Services (CMS) on the proposed 2024 MPFS and OPPS rules, encouraging CMS to finalize many new Medicare proposals, with several modifications. ASAM joined several other organizations in a letter to the leadership of the House Committee on Oversight and Accountability opposing the U.S. Shipping Equity Act (H.R. 3721) that would allow the U.S. Post Office (USPS) to ship beverage alcohol. ASAM signed a letter supporting the Helping Tobacco Users Quit Act (H.R. 4775), which would ensure Medicaid and Childrens Health Insurance Program (CHIP) enrollees have access to all evidence-based tobacco cessation treatments, including seven Food and Drug Administration-approved medications. Advocated for DEA related clarifications or changes to registration requirements related to the delivery of injectable buprenorphine. Supported S 2919 - Advancing Lifesaving Efforts with Rapid Test Strips for Communities Act (ALERT Communities Act) to help expand access to fentanyl and xylazine test strips, a critical tool to help lower overdose deaths. Supported HR 5506 - Hospitals As Naloxone Distribution Sites (HANDS) Act, which would require Medicare, Medicaid, and TRICARE to cover the cost when medical providers physically hand naloxone to patients who are at risk of an overdose, before they are discharged, at zero cost to the patient. Supported H.R.5163 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Supported S.3006 - SAFE in Recovery Act, which would ensure comprehensive wraparound services for families impacted by substance use disorders. Advocated for reforms to the Child Abuse Prevention and Treatment Act related to pregnant women who take medications for substance use disorder. Advocated for continued telemedicine flexibilities related to medications for substance use disorder.

Client expense: $40,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY24 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY24 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M) Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Worked on draft legislation that would provide Medicare coverage for evidence-based residential SUD services Supported H.R.1502 - Comprehensive Opioid Recovery Centers Reauthorization Act of 2023, in its entirety Advocated for removal of in-person evaluation requirement in proposed telemedicine rules by the DEA and worked on related draft legislation Opposed proposed changes to the STAR-LRP program in S.462 - the Mental Health Professionals Workforce Shortage Loan Repayment Act of 2023 Advocated for removal of a lifetime ban that prevents individuals convicted of a drug felony from receiving Supplemental Nutritional Assistance Program (SNAP) or Temporary Assistance for Needy Families TANF) as part of the next Farm Bill. Advocated for various substance use disorder workforce and coverage policy changes, including some of which appear in H.R. 4531, the Support for Patients and Communities Reauthorization Act. Advocated for certain annual increases for Medicare office based SUD bundled codes. ASAM signed a letter in support of S. 1378, Connecting Our Medical Providers with Links to Expand Tailored and Effective Act (the "COMPLETE Act"), which would advance collaborative care models. ASAM signed a letter sent by a broad coalition of health care clinicians, patient advocates, and other stakeholders, urging Congressional leaders to support the Centers for Medicare and Medicaid Services' (CMS) proposal to implement a Medicare billing code, known as G2211, in 2024. ASAM submitted comments to the Centers for Medicare and Medicaid Services (CMS) on the proposed 2024 MPFS and OPPS rules, encouraging CMS to finalize many new Medicare proposals, with several modifications. ASAM joined several other organizations in a letter to the leadership of the House Committee on Oversight and Accountability opposing the U.S. Shipping Equity Act (H.R. 3721) that would allow the U.S. Post Office (USPS) to ship beverage alcohol. ASAM signed a letter supporting the Helping Tobacco Users Quit Act (H.R. 4775), which would ensure Medicaid and Childrens Health Insurance Program (CHIP) enrollees have access to all evidence-based tobacco cessation treatments, including seven Food and Drug Administration-approved medications. Advocated for DEA related clarifications or changes to registration requirements related to the delivery of injectable buprenorphine. Supported S 2919 - Advancing Lifesaving Efforts with Rapid Test Strips for Communities Act (ALERT Communities Act) to help expand access to fentanyl and xylazine test strips, a critical tool to help lower overdose deaths. Supported HR 5506 - Hospitals As Naloxone Distribution Sites (HANDS) Act, which would require Medicare, Medicaid, and TRICARE to cover the cost when medical providers physically hand naloxone to patients who are at risk of an overdose, before they are discharged, at zero cost to the patient. Supported H.R.5163 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Supported S.3006 - SAFE in Recovery Act, which would ensure comprehensive wraparound services for families impacted by substance use disorders. Advocated for reforms to the Child Abuse Prevention and Treatment Act related to pregnant women who take medications for substance use disorder. Advocated for continued telemedicine flexibilities related to medications for substance use disorder.

Advocated for increased FY24 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY24 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M) Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Worked on draft legislation that would provide Medicare coverage for evidence-based residential SUD services Supported H.R.1502 - Comprehensive Opioid Recovery Centers Reauthorization Act of 2023, in its entirety Advocated for removal of in-person evaluation requirement in proposed telemedicine rules by the DEA and worked on related draft legislation Opposed proposed changes to the STAR-LRP program in S.462 - the Mental Health Professionals Workforce Shortage Loan Repayment Act of 2023 Advocated for removal of a lifetime ban that prevents individuals convicted of a drug felony from receiving Supplemental Nutritional Assistance Program (SNAP) or Temporary Assistance for Needy Families TANF) as part of the next Farm Bill. Advocated for various substance use disorder workforce and coverage policy changes, including some of which appear in H.R. 4531, the Support for Patients and Communities Reauthorization Act. Advocated for certain annual increases for Medicare office based SUD bundled codes. ASAM signed a letter in support of S. 1378, Connecting Our Medical Providers with Links to Expand Tailored and Effective Act (the "COMPLETE Act"), which would advance collaborative care models. ASAM signed a letter sent by a broad coalition of health care clinicians, patient advocates, and other stakeholders, urging Congressional leaders to support the Centers for Medicare and Medicaid Services' (CMS) proposal to implement a Medicare billing code, known as G2211, in 2024. ASAM submitted comments to the Centers for Medicare and Medicaid Services (CMS) on the proposed 2024 MPFS and OPPS rules, encouraging CMS to finalize many new Medicare proposals, with several modifications. ASAM joined several other organizations in a letter to the leadership of the House Committee on Oversight and Accountability opposing the U.S. Shipping Equity Act (H.R. 3721) that would allow the U.S. Post Office (USPS) to ship beverage alcohol. ASAM signed a letter supporting the Helping Tobacco Users Quit Act (H.R. 4775), which would ensure Medicaid and Childrens Health Insurance Program (CHIP) enrollees have access to all evidence-based tobacco cessation treatments, including seven Food and Drug Administration-approved medications. Advocated for DEA related clarifications or changes to registration requirements related to the delivery of injectable buprenorphine. Supported S 2919 - Advancing Lifesaving Efforts with Rapid Test Strips for Communities Act (ALERT Communities Act) to help expand access to fentanyl and xylazine test strips, a critical tool to help lower overdose deaths. Supported HR 5506 - Hospitals As Naloxone Distribution Sites (HANDS) Act, which would require Medicare, Medicaid, and TRICARE to cover the cost when medical providers physically hand naloxone to patients who are at risk of an overdose, before they are discharged, at zero cost to the patient. Supported H.R.5163 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Supported S.3006 - SAFE in Recovery Act, which would ensure comprehensive wraparound services for families impacted by substance use disorders. Advocated for reforms to the Child Abuse Prevention and Treatment Act related to pregnant women who take medications for substance use disorder. Advocated for continued telemedicine flexibilities related to medications for substance use disorder.

Advocated for increased FY24 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY24 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M) Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Worked on draft legislation that would provide Medicare coverage for evidence-based residential SUD services Supported H.R.1502 - Comprehensive Opioid Recovery Centers Reauthorization Act of 2023, in its entirety Advocated for removal of in-person evaluation requirement in proposed telemedicine rules by the DEA and worked on related draft legislation Opposed proposed changes to the STAR-LRP program in S.462 - the Mental Health Professionals Workforce Shortage Loan Repayment Act of 2023 Advocated for removal of a lifetime ban that prevents individuals convicted of a drug felony from receiving Supplemental Nutritional Assistance Program (SNAP) or Temporary Assistance for Needy Families TANF) as part of the next Farm Bill. Advocated for various substance use disorder workforce and coverage policy changes, including some of which appear in H.R. 4531, the Support for Patients and Communities Reauthorization Act. Advocated for certain annual increases for Medicare office based SUD bundled codes. ASAM signed a letter in support of S. 1378, Connecting Our Medical Providers with Links to Expand Tailored and Effective Act (the "COMPLETE Act"), which would advance collaborative care models. ASAM signed a letter sent by a broad coalition of health care clinicians, patient advocates, and other stakeholders, urging Congressional leaders to support the Centers for Medicare and Medicaid Services' (CMS) proposal to implement a Medicare billing code, known as G2211, in 2024. ASAM submitted comments to the Centers for Medicare and Medicaid Services (CMS) on the proposed 2024 MPFS and OPPS rules, encouraging CMS to finalize many new Medicare proposals, with several modifications. ASAM joined several other organizations in a letter to the leadership of the House Committee on Oversight and Accountability opposing the U.S. Shipping Equity Act (H.R. 3721) that would allow the U.S. Post Office (USPS) to ship beverage alcohol. ASAM signed a letter supporting the Helping Tobacco Users Quit Act (H.R. 4775), which would ensure Medicaid and Childrens Health Insurance Program (CHIP) enrollees have access to all evidence-based tobacco cessation treatments, including seven Food and Drug Administration-approved medications. Advocated for DEA related clarifications or changes to registration requirements related to the delivery of injectable buprenorphine. Supported S 2919 - Advancing Lifesaving Efforts with Rapid Test Strips for Communities Act (ALERT Communities Act) to help expand access to fentanyl and xylazine test strips, a critical tool to help lower overdose deaths. Supported HR 5506 - Hospitals As Naloxone Distribution Sites (HANDS) Act, which would require Medicare, Medicaid, and TRICARE to cover the cost when medical providers physically hand naloxone to patients who are at risk of an overdose, before they are discharged, at zero cost to the patient. Supported H.R.5163 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Supported S.3006 - SAFE in Recovery Act, which would ensure comprehensive wraparound services for families impacted by substance use disorders. Advocated for reforms to the Child Abuse Prevention and Treatment Act related to pregnant women who take medications for substance use disorder. Advocated for continued telemedicine flexibilities related to medications for substance use disorder.

Advocated for increased FY24 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY24 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M) Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Worked on draft legislation that would provide Medicare coverage for evidence-based residential SUD services Supported H.R.1502 - Comprehensive Opioid Recovery Centers Reauthorization Act of 2023, in its entirety Advocated for removal of in-person evaluation requirement in proposed telemedicine rules by the DEA and worked on related draft legislation Opposed proposed changes to the STAR-LRP program in S.462 - the Mental Health Professionals Workforce Shortage Loan Repayment Act of 2023 Advocated for removal of a lifetime ban that prevents individuals convicted of a drug felony from receiving Supplemental Nutritional Assistance Program (SNAP) or Temporary Assistance for Needy Families TANF) as part of the next Farm Bill. Advocated for various substance use disorder workforce and coverage policy changes, including some of which appear in H.R. 4531, the Support for Patients and Communities Reauthorization Act. Advocated for certain annual increases for Medicare office based SUD bundled codes. ASAM signed a letter in support of S. 1378, Connecting Our Medical Providers with Links to Expand Tailored and Effective Act (the "COMPLETE Act"), which would advance collaborative care models. ASAM signed a letter sent by a broad coalition of health care clinicians, patient advocates, and other stakeholders, urging Congressional leaders to support the Centers for Medicare and Medicaid Services' (CMS) proposal to implement a Medicare billing code, known as G2211, in 2024. ASAM submitted comments to the Centers for Medicare and Medicaid Services (CMS) on the proposed 2024 MPFS and OPPS rules, encouraging CMS to finalize many new Medicare proposals, with several modifications. ASAM joined several other organizations in a letter to the leadership of the House Committee on Oversight and Accountability opposing the U.S. Shipping Equity Act (H.R. 3721) that would allow the U.S. Post Office (USPS) to ship beverage alcohol. ASAM signed a letter supporting the Helping Tobacco Users Quit Act (H.R. 4775), which would ensure Medicaid and Childrens Health Insurance Program (CHIP) enrollees have access to all evidence-based tobacco cessation treatments, including seven Food and Drug Administration-approved medications. Advocated for DEA related clarifications or changes to registration requirements related to the delivery of injectable buprenorphine. Supported S 2919 - Advancing Lifesaving Efforts with Rapid Test Strips for Communities Act (ALERT Communities Act) to help expand access to fentanyl and xylazine test strips, a critical tool to help lower overdose deaths. Supported HR 5506 - Hospitals As Naloxone Distribution Sites (HANDS) Act, which would require Medicare, Medicaid, and TRICARE to cover the cost when medical providers physically hand naloxone to patients who are at risk of an overdose, before they are discharged, at zero cost to the patient. Supported H.R.5163 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Supported S.3006 - SAFE in Recovery Act, which would ensure comprehensive wraparound services for families impacted by substance use disorders. Advocated for reforms to the Child Abuse Prevention and Treatment Act related to pregnant women who take medications for substance use disorder. Advocated for continued telemedicine flexibilities related to medications for substance use disorder.

Advocated for increased FY24 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY24 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M) Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Worked on draft legislation that would provide Medicare coverage for evidence-based residential SUD services Supported H.R.1502 - Comprehensive Opioid Recovery Centers Reauthorization Act of 2023, in its entirety Advocated for removal of in-person evaluation requirement in proposed telemedicine rules by the DEA and worked on related draft legislation Opposed proposed changes to the STAR-LRP program in S.462 - the Mental Health Professionals Workforce Shortage Loan Repayment Act of 2023 Advocated for removal of a lifetime ban that prevents individuals convicted of a drug felony from receiving Supplemental Nutritional Assistance Program (SNAP) or Temporary Assistance for Needy Families TANF) as part of the next Farm Bill. Advocated for various substance use disorder workforce and coverage policy changes, including some of which appear in H.R. 4531, the Support for Patients and Communities Reauthorization Act. Advocated for certain annual increases for Medicare office based SUD bundled codes. ASAM signed a letter in support of S. 1378, Connecting Our Medical Providers with Links to Expand Tailored and Effective Act (the "COMPLETE Act"), which would advance collaborative care models. ASAM signed a letter sent by a broad coalition of health care clinicians, patient advocates, and other stakeholders, urging Congressional leaders to support the Centers for Medicare and Medicaid Services' (CMS) proposal to implement a Medicare billing code, known as G2211, in 2024. ASAM submitted comments to the Centers for Medicare and Medicaid Services (CMS) on the proposed 2024 MPFS and OPPS rules, encouraging CMS to finalize many new Medicare proposals, with several modifications. ASAM joined several other organizations in a letter to the leadership of the House Committee on Oversight and Accountability opposing the U.S. Shipping Equity Act (H.R. 3721) that would allow the U.S. Post Office (USPS) to ship beverage alcohol. ASAM signed a letter supporting the Helping Tobacco Users Quit Act (H.R. 4775), which would ensure Medicaid and Childrens Health Insurance Program (CHIP) enrollees have access to all evidence-based tobacco cessation treatments, including seven Food and Drug Administration-approved medications. Advocated for DEA related clarifications or changes to registration requirements related to the delivery of injectable buprenorphine. Supported S 2919 - Advancing Lifesaving Efforts with Rapid Test Strips for Communities Act (ALERT Communities Act) to help expand access to fentanyl and xylazine test strips, a critical tool to help lower overdose deaths. Supported HR 5506 - Hospitals As Naloxone Distribution Sites (HANDS) Act, which would require Medicare, Medicaid, and TRICARE to cover the cost when medical providers physically hand naloxone to patients who are at risk of an overdose, before they are discharged, at zero cost to the patient. Supported H.R.5163 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Supported S.3006 - SAFE in Recovery Act, which would ensure comprehensive wraparound services for families impacted by substance use disorders. Advocated for reforms to the Child Abuse Prevention and Treatment Act related to pregnant women who take medications for substance use disorder. Advocated for continued telemedicine flexibilities related to medications for substance use disorder.